No change in predicted risk for in-hospital and one-year mortality in patients hospitalised with heart failure during as compared to before the COVID-19 pandemic
Northwestern University, Chicago (United States of America)
0
follower
8
more
presentations
in this session
Empagliflozin use versus dipeptidyl peptidase 4 inhibitors reduces risk of cardiovascular and renal disease among type 2 diabetes patients in routine care in europe and israel: EMPRISE study results
Testing for iron deficiency and use of ferric carboxymaltose in patients with heart failure: need for implementation? data from the swedish heart failure registry